Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
$0.08 per share
Est. EPS $0.88 · Revenue $1.58B · 2 analysts
Est. EPS $0.92 · Revenue $1.54B · 2 analysts
Est. EPS $3.35 · Revenue $6.13B · 2 analysts
$0.08 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $6.2B | -2.9% | +6.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $187.0M | -78.4% | -26.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +54.1% | -6.8% | +1.4% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +20.7% | -10.9% | +13.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +3.0% | -77.7% | -30.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $538.0M | -8.5% | -65.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +8.7% | -5.8% | -67.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1170.2% | -38.9% | -10.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.82x | +13.8% | -1.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $12.9B | -1.8% | +1.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.72 vs 3.75 | -80.8% | 0.40 vs 0.91 | -56.0% |
| Revenue Surprise | $6.2B vs $6.2B | -0.1% | $1.6B vs $1.6B | -2.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Arjona Ferreira Juan Camilo | officer: Head of R&D & CMO | Common Stock | A | 11,519 | — |
| Aug 11, 2026 | Arjona Ferreira Juan Camilo | officer: Head of R&D & CMO | Common Stock | D | 4,134 | $13.62 |
| Aug 11, 2026 | Arjona Ferreira Juan Camilo | officer: Head of R&D & CMO | Restricted Stock Units | A | 11,519 | — |
| Aug 5, 2026 | Drinane Juliana Papa | officer: Head of Mfg & Supply | Common Stock | D | 14,761 | $13.57 |
| Jun 12, 2026 | Sharp Shalini | director | Phantom Stock | A | 17,857 | — |
Operator: Hello, and welcome to the Organon Fourth Quarter and Full Year 2025 Earnings Call and webcast. [Operator Instructions]. I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations. You may begin. Jennifer Halchak: Thank you, operator. Good morning, everyone. With me today are Joe Morrissey, Organon's Interim Chief Executive Officer; and Matt Walsh, our Chief Financial Officer; Carrie Cox, Organon's Board Chair; and Juan Camilo Arjona Ferreira, Organon's Head of R&D, will also be joining for the Q&A portion of this call. Today, we are referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events and Presentations section of our Organon Investor Relations website. Please reference Slides 2 and 3 for a couple of brief reminders. I would like to caution listeners that certain information discussed by management during this call will include forward-looking statements. Forward-looking statements can be identified because they do not relate strictly to historical or current facts and use words such as potential, should, will, continue, expects, believe, future, estimates, believes, outlook and other words of similar meaning. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, which are discussed in the company's filings with the Securities and Exchange Commission. This includes our most recent Form 10-K and Forms 10-Q and those amended forms. These statements are based on information as of today, February 12, 2026 and except as required by law, Organon undertakes no obligation to update or revise any of these forward-looking statements. In addition, we will discuss certain non-GAAP financial measures on this call, which should be considered a supplement to and not a substitute for financial measures prepared in accordance with GAAP. Descriptions of these measures and reconciliations to the comparable GAAP measures are included in today's earnings press release and conference call presentation, both of which are available on our Investor Relations website and have been furnished to the SEC on the current report on Form 8-K. I note that while our full year 2026 guidance measures other than revenue are provided on a non-GAAP basis, Organon does not provide GAAP financial measures on a forward-looking basis because we cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts and acquisition-related expenses. These items are uncertain, depend on various factors and could be material to our results computed in accordance with GAAP. I'd now like to turn the call over to Joe Morrissey. Joseph Morrissey: Thank you, Jen. Beginning on Slide 4. In 2025, …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Matthew Walsh | Executive Vice President & Chief Financial Officer | USD 1,687,535 | Male | 1967 | Active |
Joseph T. Morrissey Jr. | Chief Executive Officer | USD 1,657,032 | Male | 1965 | Active |
Juan Camilo Arjona Ferreira | Executive Vice President, Head of Research & Development and Chief Medical Officer | USD 1,329,831 | — | 1971 | Active |
Rachel A. Stahler | Executive VP, Chief Information Officer and Chief Digital & Growth Officer | USD 1,266,687 | Female | 1976 | Active |
Kirke Weaver | Executive Vice President, General Counsel & Corporate Secretary | USD 1,258,043 | Male | 1973 | Active |
Carrie Smith Cox | Executive Chair of the Board | USD 220,645 | Female | 1959 | Active |
Daniel Karp | Chief Strategy Officer & Head of Corporate Development | — | Male | 1978 | Active |
Aaron Falcione | Executive Vice President & Chief Human Resources Officer | — | Male | 1971 | Active |
Vittorio Nisita | Executive Vice President & Head of Enterprise Services and Solutions | — | Male | 1968 | Active |
Jennifer Halchak | Head of Investor Relations | — | Female | — | Active |
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company's Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VANCOUVER, BC / ACCESS Newswire / July 27, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties for the first half of 2026 and forecast for the remainder of the year. Highlights Approximately 44,000 metres of partner-funded drilling completed or underway on seven exploration stage projects where Orogen holds various royalty interests Over 7,000 metres of conversion drilling completed at Ermitano's Navidad/Winter deposit, where Orogen holds a cash-flowing 2% net smelter return ("NSR") royalty Received $1.72 million from the sale of projects and payments from exploration partners year to date Two new royalties created from project sales New pipeline of projects generated from partner-funded gold exploration in Nevada and Utah, and from Orogen's internally funded programs Additional six drill programs with 25,000 metres of drilling estimated in H2-2026 Paddy Nicol, CEO of Orogen, commented, "Orogen's strategy is built on a scalable business model of profitably generating highly prospective exploration stage mineral projects and advancing them through strategic partnerships, while retaining royalties.
